48 related articles for article (PubMed ID: 11761450)
21. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
Liu R; Sharom FJ
Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
[TBL] [Abstract][Full Text] [Related]
22. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.
Dey S; Ramachandra M; Pastan I; Gottesman MM; Ambudkar SV
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10594-9. PubMed ID: 9380680
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1).
Maki N; Dey S
Biochem Pharmacol; 2006 Jul; 72(2):145-55. PubMed ID: 16729976
[TBL] [Abstract][Full Text] [Related]
24. Single amino acid substitution in the putative transmembrane helix V in KdpB of the KdpFABC complex of Escherichia coli uncouples ATPase activity and ion transport.
Bramkamp M; Altendorf K
Biochemistry; 2005 Jun; 44(23):8260-6. PubMed ID: 15938615
[TBL] [Abstract][Full Text] [Related]
25. In vitro translation of a 2.3-kb splicing variant of the hamster pgp1 gene whose presence in transfectants is associated with decreased drug resistance.
Ma JF; Grant G; Staelens B; Howard DL; Melera PW
Cancer Chemother Pharmacol; 1999; 43(1):19-28. PubMed ID: 9923537
[TBL] [Abstract][Full Text] [Related]
26. Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles.
Garrigos M; Belehradek J; Mir LM; Orlowski S
Biochem Biophys Res Commun; 1993 Nov; 196(3):1034-41. PubMed ID: 7902705
[TBL] [Abstract][Full Text] [Related]
27. The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates.
Loo TW; Clarke DM
Biochemistry; 1999 Apr; 38(16):5124-9. PubMed ID: 10213617
[TBL] [Abstract][Full Text] [Related]
28. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Barakat S; Gayet L; Dayan G; Labialle S; Lazar A; Oleinikov V; Coleman AW; Baggetto LG
Biochem J; 2005 Jun; 388(Pt 2):563-71. PubMed ID: 15693753
[TBL] [Abstract][Full Text] [Related]
29. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity.
Straub P; Johnson EF; Kemper B
Arch Biochem Biophys; 1993 Nov; 306(2):521-7. PubMed ID: 8215458
[TBL] [Abstract][Full Text] [Related]
30. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein.
Isenberg B; Thole H; Tümmler B; Demmer A
Eur J Biochem; 2001 May; 268(9):2629-34. PubMed ID: 11322883
[TBL] [Abstract][Full Text] [Related]
31. Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate.
Loo TW; Clarke DM
J Biol Chem; 1997 Dec; 272(51):31945-8. PubMed ID: 9405384
[TBL] [Abstract][Full Text] [Related]
32. Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance.
Devine SE; Ling V; Melera PW
Proc Natl Acad Sci U S A; 1992 May; 89(10):4564-8. PubMed ID: 1350094
[TBL] [Abstract][Full Text] [Related]
33. An Affordable Topography-Based Protocol for Assigning a Residue's Character on a Hydropathy (PARCH) Scale.
Ji J; Carpentier B; Chakraborty A; Nangia S
J Chem Theory Comput; 2024 Feb; 20(4):1656-1672. PubMed ID: 37018141
[TBL] [Abstract][Full Text] [Related]
34. The S1 helix is a VIP in VSP.
Short B
J Gen Physiol; 2024 Jul; 156(7):. PubMed ID: 38860979
[TBL] [Abstract][Full Text] [Related]
35. Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1.
Crowley E; O'Mara ML; Reynolds C; Tieleman DP; Storm J; Kerr ID; Callaghan R
Biochemistry; 2009 Jul; 48(26):6249-58. PubMed ID: 19456124
[TBL] [Abstract][Full Text] [Related]
36. Further characterization of the sixth transmembrane domain of Pgp1 by site-directed mutagenesis.
Song J; Melera PW
Cancer Chemother Pharmacol; 2001 Nov; 48(5):339-46. PubMed ID: 11761450
[TBL] [Abstract][Full Text] [Related]
37. Transmembrane domain (TM) 9 represents a novel site in P-glycoprotein that affects drug resistance and cooperates with TM6 to mediate [125I]iodoarylazidoprazosin labeling.
Song J; Melera PW
Mol Pharmacol; 2001 Aug; 60(2):254-61. PubMed ID: 11455011
[TBL] [Abstract][Full Text] [Related]
38. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
Dey S; Hafkemeyer P; Pastan I; Gottesman MM
Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
[TBL] [Abstract][Full Text] [Related]
39. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
[TBL] [Abstract][Full Text] [Related]
40. N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Wang Y; Georges E
Anticancer Res; 1997; 17(1A):357-64. PubMed ID: 9066677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
